Exploring Emerging Immunotherapies in Melanoma

Release Date: November 4, 2021
Expiration Date: November 4, 2022

Acknowledgement of Commercial Support

This activity is funded by PER^®.
 

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Describe the mechanism of actions of novel immune checkpoint inhibitors for the treatment of cancer.
• Explain the rationale for using emerging immunotherapies for the management of cancer.
• Assess key data from ongoing clinical trials evaluating novel immune checkpoint inhibitors for the treatment of cancer

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible entities
 

Faculty

Omid Hamid, MD
Director, Melanoma Center and Phase 1 Immuno-Oncology Program
Chief, Immunotherapy and Translational Research
The Angeles Clinic and Research Institute
Director, Melanoma Program
Cedars Sinai Samuel Oschin Comprehensive Cancer Institute
Los Angeles, CA

Disclosures: Consultant: Aduro, Akeso Biopharma, Amgen, BeiGene, BioAtla, Bristol Myers Squibb, Roche, Genentech, GlaxoSmithKline, lmmunocore, ldera Pharmaceuticals, lncyte, Janssen Pharmaceuticals, Merck & Co., NextCure, Novartis, Pfizer, Sanofi Regeneron, Seagen, Tempus, Zelluna Immunotherapy AS. Speaker's Bureau: Bristol Myers Squibb, Novartis, Pfizer, Sanofi Regeneron. Other Support (please specify): Contracted Research for Institution: Arcus Biosciences, Aduro, Akeso Biopharma, Amgen, BioAtla, Bristol Myers Squibb, CytomX Therapeutics, Exelixis, Roche Genentech, GlaxoSmithKline, lmmunocore, ldera Pharmaceuticals, lncyte, lovance Biotherapeutics, Merck & Co., Moderna, Merck Serono, NextCure, Novartis, Pfizer, Sanofi Regeneron, Seagen, Torque Pharmaceuticals, Zelluna Immunotherapy AS.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.